Lymphocyte Activation Gene 3 (LAG3) Antibody
221€ (50 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Lymphocyte Activation Gene 3 (LAG3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx323649
tested applications
ELISA, WB
Description
LAG3 Antibody is a Rabbit Polyclonal against LAG3.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Lymphocyte Activation Gene 3 (LAG3) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | ELISA: 1/20000, WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µg |
| Size 2 | 100 µg |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P18627 |
| Gene ID | 3902 |
| Alias | Lymphocyte activation gene 3 protein ,CD223,LAG-3,FDC |
| Background | Antibody anti-LAG3 |
| Status | RUO |
Descripción
LAG3 (lymphocyte-activation gene 3), also known as CD223, is a cell surface protein that plays a critical role as an immune checkpoint inhibitor. It functions as a negative regulator of T cell activity and is predominantly expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells. LAG-3 belongs to the immunoglobulin (Ig) superfamily and is structurally similar to CD4, although it performs an inhibitory rather than activating function. Its primary ligand is the major histocompatibility complex (MHC) class II, and it binds with much higher affinity than CD4, providing it with strong immunoregulatory capabilities. As an immune checkpoint receptor, LAG-3 is critical for maintaining immune homeostasis and preventing autoimmune reactions by moderating immune responses. Its expression is upregulated during chronic infections and in cancer, often contributing to T cell exhaustion, a state in which T cells progressively lose function due to prolonged antigen exposure. This makes LAG-3 a therapeutic target in immuno-oncology and chronic infection therapies. The blockade of LAG-3 has shown potential in restoring T cell function, thereby enhancing anti-tumor and anti-pathogen immune responses.
Related Products
Human LAG3(Lymphocyte activation gene 3 protein) ELISA Kit
Ver Producto
anti- LAG-3 antibody
Ver Producto